Genetics is influencing more and more of our decisions, but we can’t make the right choices if we don’t understand it.
Efficiently translating genomic research into the clinic is one of the most important steps in the development of the field. The clinic is where we will see things come to fruition.
In this open discussion webinar, DNA Genotek and Illumina discuss what’s trending in whole genome sequencing (WGS).
Our ability to reconstruct physical features from DNA is advancing, but can we ensure the privacy of “anonymised” genetic data if we can predict the face of its owner?
The U.K. Prime Minister, Theresa May has made her first appearance in a series on industrial strategy, whereby she has pledged millions of pounds of government funding to develop artificial intelligence to transform outcomes through early diagnosis of cancer and chronic disease.
For those planning to become parents, advances in sequencing technologies could make preconception carrier screening more useful by looking at a much broader set of genes.
A new chemotherapy regime has proved to shrink tumours twice as fast as in normal methods in patients with aggressive breast cancer carrying a faulty BRCA gene, according to a clinical trial.
Geisinger Health System CEO, Dr. David Feinberg reveals health system’s pioneering precision health efforts will be recommended to every patient.
Cryptographic system could enable ‘crowdsourced’ genomics, with volunteers contributing information to privacy-protected databases.
A new cell-based medicine is offering hope for children suffering from incurable nerve tissue cancer, posing a dilemma for investors.
For the first time, scientists have revealed the essential genes for the most deadly human malaria parasite, Plasmodium falciparum. They have created new genomic techniques to analyse every gene in the parasite and determine which ones are indispensable.
Now, Salk researchers have demonstrated in mice that haemophilia B can be treated for life with one single injection, containing disease-free liver cells that can produce their missing clotting factor.
Thermo Fisher Scientific has signed agreements with Takeda Pharmaceuticals and Daiichi Sanyo that will enable the Japanese firms to leverage Thermo Fisher’s FDA approved Oncomine Dx Target Test for their clinical trials and drug development programs.